Menu
← Oncology Approval Tracker
FDA DECISION ·
Inluriyo + Verzenio
imlunestrant with abemaciclib · Eli Lilly
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Adults with advanced or metastatic ER-positive, HER2-negative breast cancer with an ESR1 mutation identified by an FDA-authorized test, after progression on at least one endocrine therapy line.
LAMPGEN ANALYSIS
Why it matters
This combines an oral estrogen receptor antagonist with a CDK4/6 inhibitor in ESR1-mutated disease after endocrine progression. The prior-progression requirement distinguishes this decision from mutation-triggered switching before progression.
What research teams should watch
Capture the ESR1 test result, endocrine progression date and treatment history. The companion diagnostic and regimen-specific safety checks belong in the same handoff.
PRIMARY RECORDS